%0 Systematic Review
%T The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis.
%A Li B
%A Deng H
%A Lei B
%A Chen L
%A Zhang X
%A Sha D
%A Li B
%A Deng H
%A Lei B
%A Chen L
%A Zhang X
%A Sha D
%J Front Oncol
%V 12
%N 0
%D 2022
%M 36249067
%F 5.738
%R 10.3389/fonc.2022.985377
%X UNASSIGNED: Recent studies have shown that the fibrinogen to albumin ratio (FAR) is closely related to the prognosis of various cancers. The aim of this systematic review and meta-analysis was to investigate the prognostic value of FAR in malignancies based on the available evidence.
UNASSIGNED: To systematically search the Cochrane Library, Embase, PubMed, Google Scholar, Baidu scholars, CNKI and VIP databases for relevant studies published before April 1, 2022, and to evaluate the fibrinogen-to-albumin ratio (FAR) and survival of patients with malignant tumors through a meta-analysis relationship between the results. Results. This meta-analysis included 19 eligible studies involving 5926 cancer patients. We found that high FAR was associated with poor overall survival (HR=2.25, 95%CI 1.86-2.74, p<0.001), recurrence-free survival (HR=2.29, 95%CI 1.91-2.76, P<0.001), progression-free survival (HR: 2.10, 95%CI 1.58-2.79, p<0.001), disease-free survival (HR=1.52, 95%CI 1.17-1.96, p=0.001), and time to recurrence (HR: 1.555, 95%CI 1.031-2.346, P=0.035) was significantly correlated.
UNASSIGNED: High FAR is significantly associated with poor clinical outcomes in cancer, suggesting that it may be an important predictor of prognosis in patients with malignancies.